Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177 · View on ClinicalTrials.gov ↗
Study Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (20)
Missouri
- Mercy Clinic Oncology and Hematology - Joplin — Joplin
- Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center — Springfield
- Washington University School of Medicine — St Louis
- Mercy Clinic Oncology and Hematology - Sindelar Cancer Center — St Louis
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center — St Louis
Ohio
- Aultman Hospital — Canton
- TriHealth Cancer Institute — Cincinnati
- Ohio State University — Columbus
- OhioHealth Research Institute — Columbus
- Toledo Clinic Cancer Center — Toledo
Arkansas
- Mercy Clinic Oncology - Fort Smith — Fort Smith
California
- MemorialCare — Fountain Valley
Maryland
- The Center for Cancer and Blood Disorders — Bethesda
Nebraska
- Nebraska Cancer Specialists — Omaha
North Carolina
- Southeastern Medical Oncology Center — Goldsboro
Oklahoma
- Mercy Clinic Oncology and Hematology - Coletta — Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05234177
The ClinicalTrials.gov registry entry for NCT05234177 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempus AI, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention — of which Observation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05234177 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Missouri, Ohio, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05234177 about?
NCT05234177 is a clinical study titled "Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays". The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
What is the current status of trial NCT05234177?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-06-21. Estimated completion is 2029-02.
What conditions does trial NCT05234177 study?
This clinical trial studies the following conditions: Colorectal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05234177?
The interventions under investigation include: Observation (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05234177?
This trial is sponsored by Tempus AI, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05234177 being conducted?
This trial has 20 study locations across Arkansas, California, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.